Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.174 EUR | +0.97% | -3.88% | -10.19% |
May. 29 | Sales in Milan; but Philogen is at annual peak | AN |
May. 29 | Milan opens in red; new grits for MPS | AN |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The firm trades with high earnings multiples: 26.41 times its 2024 earnings per share.
- With an enterprise value anticipated at 4.21 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Distillers & Wineries
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.19% | 11.96B | B | ||
-4.49% | 286B | C+ | ||
+4.55% | 78.63B | C+ | ||
+4.60% | 40.65B | D+ | ||
-2.55% | 35.54B | C+ | ||
-15.08% | 19.41B | C+ | ||
+7.69% | 16.01B | C | ||
+3.73% | 9.86B | B- | ||
+8.80% | 9.13B | C- | ||
+4.95% | 7.69B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CPR Stock
- Ratings Davide Campari-Milano N.V.